Erez Aminov sold $134k of MIRA
Chief Executive Officer at MIRA PHARMACEUTICALS, INC.. 100,000 shares at an average of $1.34, traded Nov 19, 2024, filed Nov 27, 2024.
Score components
- +25RoleCEO
- +11Trade size$134k at market
- 0Share of holdings soldSold 8.6% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.1%, 3m -18.9%, 6m +5.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-24-047998, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2024 | SOpen-market sale Common Stock10b5-1 | -55,410 | $1.39 | $77k | 1,105,790 | Nov 27, 2024 |
| Nov 20, 2024 | SOpen-market sale Common Stock10b5-1 | -44,590 | $1.27 | $57k | 1,061,200 | Nov 27, 2024 |
Related signals
Other insiders at MIRA PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | MIRAbuy MIRA PHARMACEUTICALS, INC. | Erez Aminov Chief Executive Officer | $8,176 8,700 shares | +2% | |
| 33Weak | MIRAsell MIRA PHARMACEUTICALS, INC. | Brian Patrick McNulty owner | $726k 238,095 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.